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Abstract
Integration of the reverse transcribed viral genome into host chromatin is the hallmark of retroviral replication. Yet,
during natural HIV infection, various unintegrated viral DNA forms exist in abundance. Though linear viral cDNA is
the precursor to an integrated provirus, increasing evidence suggests that transcription and translation of
unintegrated DNAs prior to integration may aid productive infection through the expression of early viral genes.
Additionally, unintegrated DNA has the capacity to result in preintegration latency, or to be rescued and yield
productive infection and so unintegrated DNA, in some circumstances, may be considered to be a viral reservoir.
Recently, there has been interest in further defining the role and function of unintegrated viral DNAs, in part
because the use of anti-HIV integrase inhibitors leads to an abundance of unintegrated DNA, but also because of
the potential use of non-integrating lentiviral vectors in gene therapy and vaccines. There is now increased
understanding that unintegrated viral DNA can either arise from, or be degraded through, interactions with host
DNA repair enzymes that may represent a form of host antiviral defence. This review focuses on the role of
unintegrated DNA in HIV infection and additionally considers the potential implications for antiviral therapy.
Review
Multiple forms of unintegrated DNA
The retrovirus family is characterized by reverse tran-
scription of the viral RNA genome to cDNA and its
integration into the host cell genome. Integration of the
reverse transcribed cDNA is mediated by the viral
encoded and imported integrase enzyme. Integrase
excises a dinucleotide from the 3’ terminus of the
cDNA in a step known as 3’ processing. 3’ processed
viral DNA is then covalently linked to host DNA in a
process known as strand transfer [1]. Single stranded
DNA breaks, in the host genome at the site of integra-
tion, are then repaired by host factors [2]. The viral gen-
ome is preferentially integrated into transcriptionally
active open chromatin [3-5], following the transcription
of viral genes which occurs via host transcription fac-
tors, leading to synthesis of the viral transactivating pro-
tein, Tat, and subsequent Tat mediated transactivation
of the viral LTR promoter. This process ensures that
viral genes integrated in the host genome are tran-
scribed, ultimately leading to synthesis of viral proteins
and completion of the viral replication cycle [2].
However, during natural HIV-1 infection the vast
majority of viral cDNA exists in an unintegrated state
[6-10]. Multiple forms of unintegrated viral DNA exist,
including linear cDNA, the most abundant form that is
the direct product of reverse transcribed viral RNA and
is the substrate for the integration reaction [6]. All other
unintegrated DNA products derive from linear cDNA
and are circular in form (Figure 1).
Unintegrated circles can be produced through autoin-
tegration (sometimes called suicidal integration), in
which the 3’-ends of the reverse transcript are processed
by integrase and then attack sites within the viral DNA,
producing either internally rearranged or less than full
length DNA circles (Figure 1) [2,11]. Autointegration is
seen in murine Moloney leukemia virus (MoMLV),
Rous Sarcoma Virus (RSV) and HIV-1 infections, and is
thus a likely common feature of retroviral replication
[12-14]. This process occurs with relatively high fre-
quency, and so approximately 20% of the circular DNA
products were found to be autointegrants in MoMLV
infections [12].
1-LTR circles are found exclusively in the nucleus and
can be formed through homologous recombination of
linear DNAs at the LTRs, resulting in a circular DNA
bearing one copy of the viral LTR (Figure 1). Early
experiments determined that cellular factors were
required to mediate 1-LTR circle formation [15]. Later
analysis showed that the RAD50/MRE11/NBS1 nuclease
components were implicated in 1-LTR circle formation
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reproduction in any medium, provided the original work is properly cited.[16]. However, 1-LTR circles can also be formed via
ligation of interrupted reverse transcription intermedi-
ates (Figure 1) [17]. Interestingly, Foamy virus particles,
which can complete endogenous reverse transcription in
the virion prior to infection, have been shown to contain
1-LTR circles [18]. In HIV, however, endogenous
reverse transcription does not occur naturally, and even
in vitro assays do not yield near full-length products, so
it is unlikely that HIV 1-LTR circles could form outside
the cell [19]. In this regard, it must be noted that 1-LTR
circles are also absent in the cytosolic fraction of HIV-
infected cells [15]. Formal quantification of 1-LTR cir-
cles via quantitative polymerase chain reaction (qPCR)
is technically challenging, due to a lack of unique
sequence features, although end point blot and PCR
analysis methods do exist for detection of 1-LTR circles
[20,21].
The elucidation of the rolling circle hypothesis of
phage DNA replication was formulated in 1968 [22,23],
and led to the appealing hypothesis that 2-LTR circles,
that contain the full length HIV DNA and both sets of
LTRs, might be the direct precursor of integrated DNA
(Figure 1). Although some experiments suggested that
2-LTR circular DNA could bind cellular target DNA
[24], this hypothesis has since been disproven, and it is
now established that linear cDNA is the only precursor
to proviral DNA [25-27]. Accordingly, unintegrated cir-
cular products cannot sustain replication in themselves
and have been considered to be the “dead end products
of abortive infections” [2,28,29].
It is now known that 2-LTR circles are the products
of non-homologous end joining (NHEJ) DNA repair
events that are mediated in the nucleus as a protective
host response to the presence of double stranded DNA
[10,11] (Figure 1). It has been seen that viral cDNA
replication intermediates are associated with host Ku
components of the NHEJ pathway [30-32]. Additionally,
inactivation of the NHEJ components Ku, ligase 4 or
linear cDNA
auto-
integration
host DNA
repair recombination
integration
2-LTR circle 1-LTR circle
truncated
autointegrant
internally rearranged
autointegrant
degradation
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Figure 1 The various forms of unintegrated HIV cDNA. Linear cDNA, the product of reverse transcription, is susceptible to a number of fates
other than integration into host chromatin as proviral DNA. Autointegration may lead to the formation of truncated or internally rearranged
circular forms. Although recombination may yield 1-LTR circles, host factors may also contribute their presence. Host factors, such as those
involved in the non-homologous end joining pathway, participate in the formation of 2-LTR circles. Various DNA repair factors and restriction
factors may also result in direct degradation of linear cDNA. Collectively, these processes help to explain patterns of unintegrated viral DNA
present in infected cells.
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tion, whilst inhibition of the DNA-dependent protein
kinase catalytic subunit (DNA-PKcs), which is also a
component of the NHEJ machinery, had a more modest
but measurable effect on 2-LTR circle formation [16,32].
When specific NHEJ processes were abolished in some
studies, apoptosis was seen in infected cells [30,33].
Under these circumstances, reverse transcription but
not integration was required to yield apoptosis, implicat-
ing unintegrated viral cDNA as a key signal that pro-
motes apoptosis when NHEJ processes are depleted [30].
It was previously considered that the cytopathic effect
of HIV might actually be due to excessive accumulation
of unintegrated cDNAs upon superinfection, as their
presence would trigger apoptosis even in infected cells
with intact NHEJ machinery [34-36]. But cytopathic
effect has since been proven to be separable from accu-
mulation of unintegrated DNA [37,38].
Given that 2-LTR circles are exclusively found in the
nucleus, they have become a useful marker of viral
nuclear import in studies of viral trafficking [39]. This is
due to the unique nature of the LTR-LTR junction that
can be readily assayed by PCR [40]. Thus, levels of 2-
LTR circles are often recognized as overall markers of
total unintegrated DNA in the cell, despite the fact that
2-LTR circles are present at relatively lower levels than
other unintegrated DNA species [15,40]. However,
detection sensitivity of 2-LTR circles (and other non-
integrated forms) can be improved by separating high
molecular weight mass genomic DNA from samples
[41-43].
Host cell factors that inhibit viral integration
Other than circularization by NHEJ machinery resulting
in 2-LTR circles, there are many further mechanisms
that recognize and neutralize infecting retroviral DNA.
These involve a variety of factors, many of which are
involved in cellular DNA repair processes. For example,
XPB and XPD are cellular DNA helicases that are com-
ponents of the TFIIB basal transcription complex that
plays a role in DNA nucleotide excision repair [44].
Recently, XPB and XPD also were implicated in control-
ling retroviral infection [45,46]. In comparison to cells
which have reduced XPD and XPB function, it was
shown that retroviral cDNA is degraded in wild type
cells in the absence of an accumulation of 2-LTR circles.
This implies an XPB- and XPD-mediated mechanism of
linear viral cDNA degradation. Further analysis has
shown that XPB-mediated degradation of retroviral
cDNA is dependent on nuclear entry. However, these
restrictive effects do not involve XPB and XPD mediated
up-regulation of host gene expression or induction of
APOBEC3G or other proteasome-mediated pathways
[46].
There are similar findings involving other DNA repair
mechanisms; Rad18 is a component of the post-replica-
tion DNA repair pathway which was identified as contri-
buting to HIV integrase stability [47]. More recent
analysis demonstrated that cells lacking Rad18 were
hyper susceptible to infection by MLV and HIV [48].
T h i se f f e c tw a se v e ns e e nw i t hn o n - i n t e g r a t i n gv i r u s ,
leading to the conclusion that Rad18 perhaps exerts its
influence on viral cDNA prior to integration. Another
example of the involvement of DNA repair pathways in
preventing retroviral infection is found in the homolo-
gous recombination (HR) DNA repair protein Rad52
[49]. In cells with reduced Rad52 expression, increased
levels of HIV-1 transduction were observed upon infec-
tion, yet reductions in levels of other HR components
(XRCC2, XRCC3 and BRCA2) had no such effect. Inter-
estingly, 2-LTR circle levels were found to be reduced in
infected cells that over-expressed Rad52, yet there was
no apparent effect on apoptosis. These observations
imply a direct degradation of linear viral cDNA by
Rad52.
The well characterized restriction factors APOBEC3G
and APOBEC3F may also influence the forms of uninte-
grated DNA seen upon HIV infection. APOBEC3G and
APOBEC3F are nucleic acid editing enzymes which
restrict viral replication by introducing cytidine to uracil
changes in first strand synthesis of viral DNA, resulting
in mutated virus [50]. APOBEC3G and APOBEC3F are
also thought to function more directly by inhibiting viral
reverse transcription, and there now is also evidence
that APOBEC3G and APOBEC3F also directly inhibit
integration by modifying the linear cDNA substrate,
thus rendering it unsuitable for provirus formation
[51,52]. APOBEC3G generates a 6 base extension at the
U5 end of the viral 3’ LTR which causes the linear
cDNA to be a less suitable substrate for integrase,
whereas APOBEC3F, which has a more potent affect
upon integration, functions by inhibiting the 3’ proces-
sing of the viral cDNA prior to integration. Curiously,
APOBEC3G-mediated inhibition of integration leads to
a two-fold reduction in 2-LTR circles upon infection
with a Δ-vif virus when compared controls lacking
APOBEC3G [53]. It is possible that the inhibition pro-
cess may render the linear cDNA template a less suita-
ble substrate for the cellular NHEJ machinery leading to
less 2-LTR circle formation, and/or there may be a
direct degradation of the modified cDNA.
Another DNA repair factor, uracil DNA glycosylase 2
(UNG2), which is part of the uracil base excision repair
pathway, is thought to directly inhibit retroviral DNA at
a preintegration step [54], a process which may be
counteracted by HIV-1 Vpr [55]. Yet, the precise role of
UNG2 in the HIV lifecycle remains controversial; some
evidence suggests that UNG2 may be required to
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cessful reverse transcription [56], but there is also evi-
dence that indicates a lack of involvement of UNG2 in
APOBEC3G-mediated effects on infectivity [57]. Recent
data also suggests that HIV DNA tolerates a high rate
of uracilation, rendering it a poor target for strand
transfer when compared to uracil-poor chromosomal
DNA, a process which seems to protect viral DNA from
autointegration [58]. These contradictory findings make
it difficult to reconcile the true role of UNG2 in HIV
replication.
Accordingly, multiple host factors involved in DNA
repair serve to subvert retroviral infection, resulting in
the formation of retroviral cDNA circles. Additionally,
other DNA repair mechanisms directly degrade or mod-
ify viral linear cDNA and may act in conjunction with
constituents of the intrinsic/innate immunity responses,
in order to prevent viral integration. The importance of
these restrictive measures to the host cell is demon-
strated by the finding that NHEJ genes in both yeast
cells and primates were under strong selective pressure,
indicating a competition between host and pathogen
[59,60]. Collectively, these processes help to explain the
observation that the majority of reverse transcribed
DNA does not obtain the status of integrated viral DNA
[61,62].
Host cell factors that aid viral integration
HIV uses cellular host factors to increase the likelihood
of successful integration. One of the best characterized
is LEDGF/p75 which is required to tether viral DNA to
host chromatin in association with integrase, and also
aids virus to preferentially integrate in open chromatin
[63-65]. Blocking the integrase-LEDGF/p75 interaction
with small molecule inhibitors leads to elevated levels of
2-LTR circles [66]. The host factor HMG I(Y) has been
shown to be a component of the pre-integration com-
plex (PIC) for both HIV-1 and MoLV. Although HMG I
(Y) can stimulate integration in vitro, cells depleted of
HMG I(Y) were not defective in regard to HIV infection
[67-70]. Another factor which aids integration is the
host protein INI 1, also known as SNF5. INI 1, is a core
component of the ATP-dependent chromatin remodel-
ling complex SWI/SNF and is also a component of the
PIC which can stimulate HIV-1 integrase activity in
nucleosome regions of chromatin [71,72]. Thus, multiple
host factors are components of the PIC and act in con-
cert to promote the success of the integration reaction;
it is possible that more such factors remain to be
identified.
Once the integration reaction has been completed,
cellular DNA repair enzymes are thought to be used to
repair the strand break after the viral genome has been
tethered to that of the host. Although the data available
provide a far from complete picture, members of the
PIKK family, i.e. ATM, DNA-PKcs and ATR have all
been implicated in this process [33,73,74]. However,
some studies found no influence on HIV-1 transduction
when ATM, ATR, DNA-PKcs, and PARP-1 were
knocked down [75]. Surprisingly, DNA-PKcs when
knocked down led to slightly lower levels of 2-LTR cir-
cles, meaning that DNA-PKcs has been described to
have both a positive and negative effect on the integra-
tion process [16,33]. Although Ku70 depletion can lead
to reductions in 2-LTR circle formation, it has also
recently been suggested that Ku70 also protects viral
integrase from ubiquitination and subsequent degrada-
tion, or that Ku70 may be involved in DNA repair after
integration of viral DNA into host chromatin, suggesting
a positive role for Ku70 in HIV replication [32]. In order
to identify novel host factors required for successful
integration, an siRNA screen was recently performed
that targeted components of cellular DNA repair
mechanisms [76]. This process identified proteins
involved in base excision repair (BER) as factors
required for efficient lentiviral, but not gamma retro-
viral, integration. Further analysis of this screen charac-
terized the role of the damage recognition glycosylases
OGG1 and MYH and the late repair factor POLb as
ones that can augment lentiviral integration, although
the mechanistic basis for this is as yet unknown, the
authors propose that BER proteins might help to com-
plete repair of the integration intermediate [77].
Retroviruses may also use host factors to increase the
efficiency of integration, by reducing the likelihood of
autointegration. For MoMLV, the host-derived barrier
to autointegration factor (BAF) was found to be a com-
ponent of the PIC which protects viral cDNA from
autointegration [78]. In vitro analyses of HIV-1 PICs
also found that BAF also functioned in this manner
[79]. However, despite clear in vitro activity, for HIV the
knockdown of BAF in cells did not seem to prevent
viral replication [80]. HIV-1 and HIV-2 also use compo-
nents of the endoplasmic reticulum-associated SET
complex, which consists of three DNAses (APE1,
TREX1, and NM23-H1), to prevent autointegration.
Knockdown of these components measurably increased
levels of viral autointegrants following infection [13].
Little is understood about the process, but a direct
interaction between the SET complex and the PIC was
observed. However, this effect did not extend to either
murine leukemia virus (MLV) or avian sarcoma virus
(ASV). Given the propensity for retrovirus to autointe-
grate, it will be interesting to uncover what methods
viruses have evolved to counteract this process.
Thus, viral cDNA undergoes a series of complex posi-
tive and negative interactions with host factors during
integration into host chromatin. These interactions
Sloan and Wainberg Retrovirology 2011, 8:52
http://www.retrovirology.com/content/8/1/52
Page 4 of 15ultimately dictate the levels and proportions of uninte-
grated DNA species that are observed upon retroviral
infection by either influencing the likelihood that certain
unintegrated DNA species are formed, by promoting
degradation of unintegrated DNA species, or by promot-
ing the likelihood that linear cDNA becomes provirus
(Figure 1).
Transcription of viral genes from unintegrated HIV DNA
The primary function of unintegrated DNA in the HIV
replication cycle is to provide the link between viral
RNA and integrated proviral DNA, in the form of linear
cDNA [2]. Yet, when viral integration may not yet have
occurred, transcription of viral genes can still be
observed [81,82]. Some experiments have used inte-
grase-defective viruses, in which various point mutations
were inserted into the amino acids of the catalytic triad
D(64)D(116)E(152), to yield a non-functional integrase
domain of the pol polyprotein which becomes packaged
into an otherwise functional virion [83]. Common muta-
tions for this approach are D64E, D116N and E152A,
but inhibitory concentrations of integrase strand transfer
inhibitors, such as raltegravir, can also be used to block
integration [84].
Using these approaches, it has been shown that virally
imported Vpr can promote the transcription of viral
g e n e sf r o mu n i n t e g r a t e dD N A ,ap r o c e s st h a ti si n d e -
pendent of Tat transactivation [85]. This process of
Vpr-mediated transcription may ultimately lead to Tat
expression and subsequent positive feedback of the tran-
scription process from unintegrated DNA via Tat. Thus,
one role of virally imported Vpr may be to initiate tran-
scription and early Tat synthesis (Figure 2).
When transcription from unintegrated DNA does
occur, all classes of multiply-spliced, singly spliced and
unspliced viral mRNA transcripts can be observed (Fig-
ure 2) [86-88]. However, the relative proportions of each
splice class vary compared to those observed during
productive infection, i.e. whilst multiply spliced tran-
scripts are abundant in the absence of integration, levels
of singly-spliced and unspliced transcripts are reduced
in this circumstance [86,87]. Both integrating and non-
integrating virus produced similar levels of multiply
spliced viral mRNA transcripts in infections of the Rev-
CEM T-cell line when assayed by qRT-PCR [81].
Another study described a transcript unique to the
LTR-LTR junction of 2-LTR circles, though it is
unknown if this transcript fulfils any function [89].
Despite extensive transcription from unintegrated
DNA, a key limitation in the translation of viral genes
leading to the expression of late viral gene products is
t h el o wl e v e l so fR e vt h a ta r et r a n s c r i b e df r o mu n i n t e -
grated DNA. A paucity of Rev limits the nuclear export
of Rev-response-element (RRE) bearing-singly-spliced
and unspliced transcripts, which code for structural pro-
teins or are incorporated into nascent virions. Providing
Rev in trans can rescue late gene synthesis [88].
In the case of the Rev-CEM indicator cell line [90],
transcription of GFP is under the control of the HIV-1
LTR, and the gene is surrounded by splice donor and
acceptor sites downstream of a RRE [91]. This cell line
w a sm a d eb yt r a n s d u c i n gt h ep a r e n t a lC E M - S ST - c e l l
line with the pNL-GFP-RRE-SA construct. In the pre-
sence of Tat, the viral LTR is transactivated and mRNA
produced, but, if Rev is absent, the GFP coding
sequence is spliced out and not translated. Thus, GFP is
expressed in infected cells due to the presence of both
Tat and Rev; this is also the case for integrase defective
infections, as Tat and Rev can also be expressed from
an unintegrated template [92]. As the system is co-
dependent on Rev, there is very little transactivation of
the viral LTR by cellular factors as occurs with reporters
that are dependent only on Tat [90]. The cell line is
therefore useful for detecting transcriptionally active
viral infections by GFP, even from non-integrated tem-
plates, as was seen in a study that characterized the
degree of transcription from preintegrated HIV [92].
Previous calculations, based on Tat transactivation of
the viral LTR alone in HeLa-CD4-LTR-b-Gal indicator
cells, estimated that total transcription from uninte-
grated templates following infection with integrase
defective virus was about 10% of that for productive
infections [93]. The Rev-CEM-based study, using a par-
allel approach, showed that expression from integrase-
defective virus was around 70% of that of productive
infections [92]. The higher level of LTR transactivation
from cellular factors in the earlier study could have
resulted in a high background readout that masked
detection of some transcripts, a problem avoided with
the more specific Rev/Tat co-dependent approach.
The second goal of the study was to address the nat-
ure of the transcriptional template in non-integrated
infections. It was possible to sort the transcriptionally
active cell population bearing unintegrated DNA based
on infection-induced GFP expression in Rev-CEM. 2-
L T Rc i r c l el e v e l sw e r em e a s u r e db yq P C Ri nt h eG F P
positive cells [92]. Overall, there were many fewer
detectable 2-LTR circles than the total number of
actively transcribing GFP positive cells. The authors
concluded that 2-LTR circles alone could not entirely
account for the level of transcription that was seen.
A different study aimed to define the transcriptional
capacity of each unintegrated HIV DNA template by
constructing artificial linear cDNA, 1-LTR and 2-LTR
circle mimics and transfecting each of them into HeLa
cells [94]. It was found that all three species of uninte-
grated DNA could serve as transcriptional templates,
and that 1-LTR circles in particular could lead to high
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grated HIV DNA forms yielded levels of protein synth-
esis that were an order of magnitude less than for
integrating virus. This finding, combined with the obser-
vation that there are relatively high numbers of 1-LTR
circles in comparison to the other templates, implies
that 1-LTR circles could be a major contributor towards
transcription from unintegrated templates [15]. How-
ever, this study also noted that late gene products, such
as p24, were synthesised from all unintegrated tem-
plates. This finding is at odds with studies that assayed
transcription from unintegrated DNA via viral infections
that yielded no p24 synthesis [88]. This demonstrates
that the means of delivery of viral DNA to the nucleus
might influence the level of transcription observed;
alternatively the cell type may also be a factor [93].
Nonetheless, all three forms of unintegrated DNA have
the innate potential to serve as a transcriptional tem-
plate, raising the question as to why this does not occur
to a higher level in infections.
In other studies, expression of late viral genes from
SupT1 cells and monocyte-derived macrophages
infected with integrase defective virus was augmented
through treatment of the cells with short-chain fatty
acid histone deacetylase inhibitors [95]. These findings
suggest that unintegrated DNA must be contained, in
part, in condensed chromatin structures. This was sur-
prising as studies of transfected plasmid DNA had
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Figure 2 Transcription from preintegrated or unintegrated DNA. Prior to integration, or if integration is blocked, transcription from
unintegrated cDNA may still occur, the template for which is unknown. Virally imported Vpr is important in the initial stages of viral gene
transcription. Translation of multiply-spliced RNA (msRNA) transcripts leads to expression of Tat, Nef and Rev. Levels of Rev are insufficient to lead
to the export of singly spliced and unspliced transcripts. Rev is thought to later interfere with the integration process and to thereby inhibit
superinfection. Tat and Nef collectively lead to increased cellular activation in resting T-cells. Newly synthesized Tat will also promote viral gene
transcription. Nef downregulates cell surface CD4, CXCR4, CCR5 and MHC-I (HLA Class I), thereby limiting superinfection, signal transduction and
likely resulting evasion from cytotoxic T-lymphocytes. Preintegration transcription of viral genes has also been linked to altered cytokine secretion
in both resting T-cells and macrophages.
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tained as part of open chromatin, but may be silenced
by epigenetic mechanisms over longer time periods in
stable transfections [96-98]. This suggests that the pre-
sence of viral DNA that has been part of the PIC leads
to a specific pattern epigenetic modifications and asso-
ciations with host factors that are not necessarily cap-
tured in transfection studies. These results also imply
that there is active control of transcription from uninte-
grated DNA and it will be interesting to uncover if this
influence is due to the virus or the host cell.
The issue of how transcription of viral cDNA arises
from unintegrated infections is important, since expres-
sion of early viral genes might have benefit for HIV
infection. This topic also has implications for gene ther-
apy, since delivery of non-integrating retrovirus to a tar-
get cell could lead to expression of genes of interest
without the risk of insertational mutagenesis as could
occur with integrating vectors. Therefore, understanding
and optimising gene transcription from non-integrating
lentivirus is an important endeavour [99-102].
Translation of viral genes from unintegrated DNA
It is now understood that circular unintegrated HIV
DNA is not a precursor for viral integration, so it was
surprising that one study noted that integrase-defective
virus could nonetheless yield synthesis of all viral gene
products and to productive infection itself [93]. This led
to the proposal that cell-type specific differences might
exist in the capacity of cells to sustain transcription
from unintegrated DNA. However, such synthesis of late
genes from unintegrated DNA was later understood to
be only observable in T-cell lines such as MT-2 that
were chronically infected with HTLV-1, it was later con-
cluded that the presence of transcriptionally active
HLTV was able to rescue integration-defective HIV
[103]. However, other studies have also demonstrated
that infections of various T-cell lines, activated or rest-
ing primary CD4
+ T-lymphocytes and macrophages,
may lead to expression of a limited range of viral pro-
teins in the absence of viral integration. There is evi-
dence for Tat transcripts from unintegrated DNA
[87-89]. However, there is no direct evidence for the
expression of Tat, in part due to difficulty in resolving it
through Western blot at low levels. There is however
much indirect evidence for Tat expression from uninte-
grated DNA due to its capacity to transactivate viral
LTRs [82,93]. The same is true for Rev, although Rev
transcripts have been readily identified from non-inte-
grated infections [88], there is no evidence directly
showing Rev expression in this circumstance. Nonethe-
less, its expression can be readily inferred from Tat and
Rev dependent Rev-CEM GFP reporter cells which
express GFP even when infected with integrase defective
virus [90,92]. Nef is the only viral protein that can be
readily demonstrated to be expressed from non-inte-
grated viral infections, and has been observed in a num-
ber of studies [81,87,88,104].
Tat has a role in modulating T-cell activation, and it
has been shown that expression of Tat and Nef from
unintegrated DNA in resting T-cells increases cellular
activation, IL-2 secretion and the likelihood of produc-
tive infection (Figure 2) [86]. These data show that
expression of viral genes prior to integration can assist
the infection process. It is still unclear if the fate of
every PIC imported into the nucleus is to perform this
function in order to prime cells for successful infection,
but it is a very appealing concept.
Patterns of transcription and translation prior to inte-
gration in productive infections of T-cells are identical
to those seen in the absence of integration [88]. This
suggests that studies of gene expression in which inte-
gration has been blocked are equivalent to studies of
gene expression prior to integration. Experiments that
use common mutations in the integrase DDE catalytic
triad or that employ integrase inhibitors to prevent inte-
gration, may therefore model preintegration events.
The best-studied HIV protein in this context is Nef
which is a multifunctional non-enzyme adaptor protein
that acts to subvert cellular signalling and trafficking
pathways [105]. As Nef is myristolated, it is directed to
cellular membranes, where it exerts many of its roles in
immune-evasion, cellular activation, and modulation of
virion infectivity [106,107]. The first two of those roles
indicate that it is advantageous that Nef be expressed
early in infection for viral replication. In support of this,
Nef-mediated functions are present even in the absence
of viral integration [81,86].
In addition to modulating the activation threshold of
infected CD4
+ resting T-cells, Nef can downregulate cell
surface CD4 expression in activated primary CD4
+ T-
cells infected with integrase-defective virus [108].
Another study confirmed Nef-mediated downregulation
of CD4 in the SupT1 cell line, and further demonstrated
that this activity was predominantly dependent on the
import of Vpr with the virion in order to promote the
initiation of transcription [109]. In studies using the
Rev-CEM cell line, it was seen that Nef, expressed in
the absence of integration, could downregulate each of
the chemokine co-receptors CCR5 and CXCR4, and
CD4 [104]. Thus, the products of unintegrated DNA
can promote extensive downregulation of entry recep-
tors (Figure 2). This process might be to restrict super-
infection and its associated toxicity. Indeed, Nef can
restrict superinfection via downregulation of CD4,
CCR5 and CXCR4 during productive infections
[110-112]. An additional benefit might extend to a
reduction of signal transduction through these receptors
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and apoptosis [113-115]. Whilst signal transduction fol-
lowing viral binding to coreceptors is important in
infection [114], excessive additional signalling after entry
might interfere with infection.
Rev may interact with viral integrase and the host fac-
tor LEDGF/p75 to negatively regulate integration
[116,117]. This is seen with both integrating and non-
integrating virus, thereby effectively regulating superin-
fection at the level of integration rather than entry
[117]. Expression of Rev might not significantly inhibit
the first infecting and Rev producing virus, but might
inhibit further superinfecting viruses from integrating.
The authors of these studies also demonstrated that
entry receptor downregulation contributed to restriction
of superinfection prior to integration, as additional
superinfection resistance was seen with following infec-
tion with a Δ-rev virus bearing an HIV envelope when
compared to a Δ-rev VSV-G envelope bearing pseudo-
virus. Such findings are consistent with studies showing
that downregulation of CD4 and chemokine receptors
reduces superinfection [104,108,109], and is also consis-
tent with studies that use an inducible cell line (293-
Affinofile) to control receptor and coreceptor density in
order to demonstrate that their reduction leads to pro-
portional loss of infection [118-120]. Thus, Rev and Nef
can act in concert to restrict superinfection prior to, or
without, integration (Figure 2).
Nef also has a role in immune evasion by inducing
downregulation of the human leukocyte antigen (HLA)
class I allotypes that are recognized by cytotoxic T-cells
(CTLs), i.e. HLA-A and HLA-C, while selectively not
downregulating HLA antigens recognized by NK cells
(HLA-B and HLA-E), which could respond to downre-
gulation by inducing apoptosis [121-124]. Studies of
infected Rev-CEM cells showed that Nef expressed from
unintegrated virus could downregulate HLA-ABC (i.e.
an epitope composed of HLA-A, HLA-B and HLA-C in
combination), HLA-A31, but not HLA-E, essentially
mirroring the effects seen in productive infections [81].
The extent of downregulation seen in the absence of
integration was similar to that seen in productive infec-
tion using wild type virus. Thus, the activity of Nef was
not linked to integration in regards HLA class I modula-
tion, a finding confirmed in primary activated CD4
+ T-
cells. This is also consistent with current understanding
that CTL responses are an important contributor in
immune control of HIV infection [125-127]. Thus,
another benefit of early Nef expression may be immune
evasion from CTLs for virus that has not yet integrated.
For cell types with slower replication kinetics the lag
between initiation of transcription from preintegrated
DNA and transcription of provirus might be long, pro-
viding a larger window of benefit for products of
unintegrated DNA in regard to immune evasion. In
macrophages, integration of the viral genome can take
2-3 days [128], although maximum integration levels in
a cell culture population required as many as 30 days
[87]. In resting CD4
+ T-cells, this process can take 2-3
days [86], whereas for activated CD4
+ T-cells or T-cell
lines, an average of only 12-24 hours is required [129].
In the case of resting CD4
+ T-cells, however, there may
be limitations on nuclear export of multiply-spliced viral
transcripts [130], although there is evidence of gene
expression in this state [82,86]. Thus in all HIV-1 infec-
tions the only viral DNA is unintegrated over a signifi-
cant period of time. It may be that the transcription
observed during this period is beneficial. Therefore, the
role of Tat, Nef and Rev regarding their many other
functions, but prior to integration, is unknown and
therefore remains an interesting question [105].
Persistence of unintegrated DNA in infected cells
Although other viral episomes (e.g. hepatitis B virus
(HBV) covalently closed circular DNA (cccDNA)
[131,132] and herpesvirus episomes [133,134]) can be
stable within host cells, unintegrated HIV DNA lacks an
origin of replication; and so it is not copied with each
cell division. Additionally, linear unintegrated cDNA is
more labile than circular forms inside cells [88,135]; this
pattern may be explained by host defence and DNA
repair responses directed to the presence of linear
cDNA. The ultimate stability of circular cDNA forms,
which are generally stable in cells, is then therefore lar-
gely driven by the rate of cell division [136-138].
Accordingly, a rapid rate of lymphocyte turnover and
cell division explain why 2-LTR circle levels are not well
maintained in the total CD4
+ T-cell population in
patients [138], despite cell culture data demonstrating
their relative intracellular stability [136]. Maintenance of
circular HIV cDNA in dividing cells can be rescued
when an origin of replication is introduced into inte-
grase-defective HIV [99,139]. Further, experiments that
sought to arrest the cell cycle of T-cells through use of
cell cycle inhibitors such as aphidocolin, which arrests
cells in the G1/S phase, also demonstrated that uninte-
grated DNA circle stability was increased to ≈ 5-7 days
in such cells [136,140-142].
Infections of non-, or slowly-dividing cells can occur
in vivo (e.g. naïve CD4
+ T-cells, resting memory CD4
+
T cells, and macrophages). In infections of quiescent
CD4
+ T-cells, reverse transcription can occur, but is
often not completed and displays greatly reduced
kinetics, or PICs might not be imported into the nucleus
efficiently when levels of ATP are lacking; therefore
integration can be delayed or may not occur at all
[86,143,144]. In these circumstances, unintegrated DNA
may persist in the resting cell, and viral gene
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tion of the cell prior to degradation of the functional
PIC may yield productive infection; hence this state is
referred to as preintegration latency [10,144-149]. This
form of latency is therefore more labile and functionally
quite distinct from post-integration latency that can
happen when integration occurs, but the provirus is
transcriptionally silent, an outcome that can be rendered
through a variety of host-mediated mechanisms [144].
Experiments in macrophages, which are a naturally
non-dividing population, have also demonstrated long-
evity of unintegrated DNA. One study found that
macrophages infected with integrase-defective virus still
contained cells bearing unintegrated DNA up to 30 days
post-infection [87]. Viral mRNA transcripts were detect-
able throughout as were viral proteins such as Nef. A
similar study on infected macrophages performed with
an integrase defective virus, bearing a luciferase reporter
gene showed that unintegrated DNA products were still
detectable in the cell up to 21 days post infection; luci-
ferase was detectable throughout the study period [150].
Finally, infections of animal models with integrase defec-
tive lentiviral vectors for gene therapy studies found that
such vectors were very stable in non-dividing cells for
extended periods, up to one year in some instances
[151,152]. Therefore, unintegrated HIV-1 DNA likely
has the capacity to persist in slow or non-dividing cells
in vivo.
Unintegrated DNA as a diagnostic marker
There has been interest in using 2-LTR circle titres as
measured by qPCR as a clinical diagnostic assay, since it
was hoped that their levels would be representative of
nascent infections [8]. This approach was supported by
prior observations that levels of total unintegrated DNA
decrease during highly active antiretroviral therapy
(HAART) [153,154]. These findings can be explained by
degradation of abundant linear unintegrated cDNAs
within cells and dilution of circular forms with each cell
division [6]. Subsequent studies of HIV-infected patient
samples demonstrated that measuring 2-LTR circle
levels specifically was not a reliable marker of effective
therapy when compared to plasma viral RNA
[43,135,141]. Confounding factors for this approach are
likely due to the persistence of 2-LTR circles in long
lived or non-dividing cellular reservoirs, the lag between
administration of antiviral drugs and actual blockage of
infection, and the possibility of ongoing replication, or
viral release from stable reservoirs despite seemingly
effective therapy [87,135,155].
Some of these potentially mitigating effects have been
investigated by monitoring 2-LTR circle levels in
patients during drug intensification studies in which
further drugs are added to an already successful highly-
active antiretroviral therapy (HAART) regimen. In one
such study, patients with undetectable viral load were
given the integrase inhibitor raltegravir [156]. In these
circumstances it is argued that the detection of an
increase in 2-LTR circle levels is indicative of de novo
viral infection that continues in the face HAART, but
below the detection limit of quantification of common
qRT-PCR assays. Evidence was found for a surge of 2-
LTR circles in 13/45 (29%) patients upon intensification,
yet this did not translate to a change in plasma viral
RNA levels when using a sensitive single copy assay.
This latter finding was confirmed in a randomized clini-
cal trial wherein again no decrease in plasma viral RNA
was seen with raltegravir intensification [157]. Given the
contradictory nature of these findings, it is unclear to
what extent raltegravir intensification does inhibit
ongoing infection and why an apparent inhibition of
replication does not go on to alter viral load. One sug-
gestion is that the cells in which there is a 2-LTR surge
arise from a site which does not communicate freely
with plasma [157]. However, it should be noted that a
previous small scale study of treatment intensification
using non-nucleoside reverse transcriptase inhibitors
(nnRTIs), or protease inhibitors, found that adding these
drugs had no effect on viral load using single copy
qPCR assays, implying that ongoing infection is likely
not the source of residual viremia [158]. This concept is
supported by phylogenetic evidence showing that upon
treatment interruption rebounding virus arises from a
small number of invariant clones, a finding that does
support the notion of ongoing replication [159].
Yet having knowledge about levels of 2-LTR circles
might still provide clinically useful data. A recent study
isolated env sequences from 2-LTR episomes in patients
who suspended therapy [160]. It was shown by sequence
analysis that rebounding virus matched that found in
viral episomes prior to plasma viral RNA rebound.
Thus, episomal sequences might predict the potential
for emergence of resistance mutations or altered core-
ceptor tropism. Therefore, although the value of know-
ing 2-LTR circle levels in therapy has been discredited
and is also disputed in intensification studies, sequences
deriving from such circles may still be of clinical benefit.
Further, knowing 2-LTR circle levels can still provide
useful data in clinical and pre-clinical studies in which
integrase mechanisms are being studied. For example,
elite suppressors of HIV, i.e. patients who control their
infection successfully without antiviral therapy, were
found to have lower rates of viral integration and higher
levels of 2-LTR circles than observed in patients who
were on or off HAART [161]. The mechanism underly-
ing this effect is unknown, but ex vivo analysis has
excluded a role for innate restriction factors that affect
viral integration. A more recent study of CD4
+ T-cells
Sloan and Wainberg Retrovirology 2011, 8:52
http://www.retrovirology.com/content/8/1/52
Page 9 of 15from elite controllers suggests that upregulation of cel-
lular p21 in such cells might be important in how they
resist infection, but the effects of p21 were seen at the
level of viral gene transcription and not at integration
[162]; therefore, the factor that might underlie any inte-
gration-related effects remain to be identified.
Unintegrated viral DNA and antiviral therapy
Since the development of the first integrase strand
transfer inhibitors, it has been known that their use
leads to elevated levels of unintegrated DNA as mea-
sured via qPCR for 2-LTR circles [40,84]. In the absence
of integration, there is greater substrate availability for
the cellular NHEJ pathway [30]. This phenomenon has
been of utility in cell culture studies of integrase inhibi-
tor therapy, as levels of 2-LTR circles, relative to levels
for wild-type virus, can be considered to be indicative of
integrase dysfunction [163,164].
The observation of elevated 2-LTR circle levels with
integrase inhibitors has led to some speculation that
these might influence the natural course of infection or
the success of therapy. In clinical trials, use of the inte-
grase strand transfer inhibitor raltegravir, compared to
the non-nucleoside reverse transcriptase inhibitor efavir-
enz [165-167], led to more rapid viral RNA decay
kinetics [166]. One study suggested that increased apop-
tosis in HIV-1 infected cells, due to accumulation of
unintegrated DNA, might explain these kinetics [168].
However, an alternative explanation, based on mathema-
tical modeling of the rate of viral decay in the various
infected cell types is that raltegravir acted at a later
stage of viral replication than efavirenz, and was thus
able to influence its antiviral effect on a larger popula-
tion of infected cells [128,169,170]. Confirmation of this
model was achieved in cell culture analysis, which
demonstrated that the stage of viral replication targeted
by each drug class contributes to the effectiveness of
viral RNA decay. Furthermore, the success of each drug
combination was controlled by the latest acting drug in
the combination [129].
Despite their effectiveness, integrase inhibitors are
unique in their capacity to lead to populations of cells
in being able to block replication at an early stage with
reduced cytopathic effect. Although expression of early
viral gene products in this circumstance is observed,
integrase inhibitor treated cells block infection in such a
way that the cell cannot directly contribute to viral load.
However, in patients receiving raltegravir treatment, a
s u r g ei n2 - L T Rc i r c l ep r o l i f e r a t i o ni ss e e nf o l l o w i n g
therapy [171]. This effect is only temporary in PBMCs,
as they lose unintegrated DNA with cell division
[136,138]. But it remains to be seen for how long unin-
tegrated DNA might persist in slow or non-dividing cell
types in patients receiving integrase inhibitor therapy,
given data for infections with integrase defective lenti-
viral vectors in animal models, it might be anticipated
that such a reservoir would be relatively long lived
[151,152].
The persistence of unintegrated cDNA is important
since infection in cells infected by integrase-defective
viruses can be rescued by a superinfection with wild
type virus [172,173]. The second, integrating infection
can yield Tat to promote transcription from the uninte-
grated template, resulting in synthesis of full length
genomic RNA from the unintegrated DNA. Such RNA
will be packaged into virions, providing opportunity for
recombination also [172]. These findings mirror early
observations on viral replication with integrase defective
viruses, suspected to result from HTLV-1 complementa-
tion [93]. Similar observations have been made with
integrase-competent drug resistant virus, in which drug
sensitive virus has been rescued by drug resistant virus
in cell culture [174], so there is little reason to suspect
that this could not occur with integrase inhibitor resis-
tance and unintegrated DNA. In this sense, both uninte-
grated and integrated viral DNA can be considered to
be viral reservoirs [175].
Conclusions and Perspectives
Without integration, virus cannot initiate late gene
synthesis and productive infection [28,29]. Even with
successful entry and reverse transcription, there is a rate
of attrition associated with attempts to integrate virus
into host chromatin that is mediated by host factors
[61,62]. Of the host mechanisms identified in this pro-
cess, the NHEJ pathways have perhaps been better char-
acterized [16,30], but very little is understood about the
apparent direct degradation of linear DNAs by factors
such as the cellular DNA helicases XPB and XPD
[45,46]. It is still not known how HIV overcomes the
obstacles of DNA repair and host-restriction factors
directed against pathogen DNA; as despite their func-
tion, viral integration still readily occurs in target cells.
These interactions are likely complex. For example, the
cellular nuclease Trex1 is important in controlling endo-
genous retroelements by metabolizing reverse tran-
scribed DNA [176,177]. Conversely, HIV-1 has been
f o u n dt ou s eT r e x 1t od i g e s tt h en o n - p r o d u c t i v eD N A
by-products of reverse transcription in order to evade
host nucleic acid sensing proteins and subsequent trig-
gering of innate immunity pathways [178]. Such DNA
detection may lead to apoptosis of the infected cell, a
process which may underlie CD4
+ T-cell depletion of
lymphoid tissue [179]. The relative importance of these
host-pathogen-DNA interactions is demonstrated by the
unexpected finding that primate NHEJ genes are under
strong positive selection [60]. Detailed understanding
of such defence pathways will have important
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DNA-utilizing viruses.
Persistence of unintegrated viral DNA in the nucleus
can yield extensive transcriptional activity, either before,
or in the absence of integration [81,180]. Expression of
certain gene products early in the viral life cycle could
provide an advantage to the virus e.g. effects on T-cell
activity via Tat and Nef [86], as well as downregulation
of CD4, CXCR4 & CCR5 via Nef [101,102,106], modula-
tion of HLA Class I expression via Nef [81], and restric-
tion of superinfection at the level of entry and
integration via Nef and Rev respectively [117]. It is
unclear whether all viruses perform preintegration tran-
scription, as this cannot be elucidated from studies of
cell populations. Kinetic and single cell analyses might
help to better define this process.
Despite such functionality, 1-LTR and 2-LTR circles
are dead end products of failed infections and their
demise is mediated either by host factors or by the virus
itself [16,30]. Conceivably,u n i n t e g r a t e dD N As p e c i e s
a r es i m p l yt r a n s c r i b e db e c a u s et h e ya r ep r e s e n ti nt h e
nucleus. Yet, studies of transfected versions of these
products show different patterns of gene expression,
arguing against this viewpoint [94]. Gene expression
from unintegrated DNA seems to be controlled in nat-
ural infection. The expression of early gene products
suggests a benefit for infection. However, it may be
argued that such genes that are the first to be expressed
anyway. A possible epigenetic modification of uninte-
grated DNA is intriguing given parallels with control of
gene expression in HBV and herpesvirus episomes
[95,181,182]. The nature of the transcriptional template
for preintegration transcription is unknown; all DNA
species remain candidates, although 2-LTR titres are too
infrequent to be the predominant template [92]. This
information would have relevance for gene therapy
approaches using non-integrating vectors [101].
How frequently might transcription from unintegrated
templates occur in lentiviruses? In SIVs, which are clo-
sely related to HIV, there might be benefit from a simi-
lar pattern of early gene expression [183]. Further afield,
it is interesting to consider if viruses which encode dif-
ferent, or more limited, early genes might benefit from
preintegration transcription, such as feline immunodefi-
ciency virus (FIV) that does not encode nef,b u td o e s
contain rev [184].
Preintegration latency may contribute to viral RNA
decay dynamics with therapy, but is likely to play only a
minor role [128,148,169,170]. Though it is unknown
how long unintegrated HIV DNA can persist in other
non-dividing cell types in vivo, but the results of
extended periods of gene expr e s s i o ni nm a c r o p h a g e si n
cell culture suggest a capacity to persist, over long peri-
ods [87,150]. The ability of such unintegrated DNA to
be rescued, and perhaps recombine with a second
incoming virus, might be a contributing factor to the
generation of viral diversity [172]. Drug resistant viruses
can also rescue non-resistant viruses and it is likely that
unintegrated DNA could equally contribute to diversity
in this context [174].
Conclusions
In summary, much of the true nature and function of
unintegrated DNA species still remains enigmatic, but
unintegrated DNA may well fulfil a multitude of roles in
the promotion of HIV infection.
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